RodneyBTrimbleDO

Family Medicine • Houston, TX

Addiction Medicine, Hospital Medicine/Hospitalist

Physician

Join to view full profile

Dr. Trimble is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Trimble's full profile

Already have an account?

Office
3701 Kirby Drive
Suite 1230
Houston, TX 77098
Phone+1 713-526-0005

Summary

I am board certified in Family Practice with an emphasis in MAT for Addiction Medicine as well as prevention and treatment of HIV.

Education & Training

University of Texas Southwestern Medical Center/Parkland Memorial HospitalResidency, Family Medicine, 1993 - 1995
Methodist Health System DallasResidency, Family Medicine, 1990 - 1992
Texas College of Osteopathic MedicineClass of 1990

Certifications & Licensure

TX State License 1991 - 2026
OH State License 2019 - 2025
CO State License 1995 - 2007
American Board of Family Medicine Family Medicine

Clinical Trials

Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults Start of enrollment: 2013 Mar 12
Completed
Phase 3
Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults Start of enrollment: 2015 Jan 26
Completed
Phase 3
Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) Start of enrollment: 2015 Jan 26
Completed
Phase 3
Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC Start of enrollment: 2015 Jun 29
Completed
Phase 3
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis Start of enrollment: 2015 Dec 14
Completed
Phase 3
Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed Start of enrollment: 2015 Nov 11
Completed
Phase 3
Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults Start of enrollment: 2015 Nov 11
Completed
Phase 3
Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment Start of enrollment: 2016 Apr 01
Completed
Phase 3
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2) Start of enrollment: 2016 Jul 18
Completed
Phase 3
Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection Start of enrollment: 2016 Sep 02
Active, not recruiting
Phase 3
Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants Start of enrollment: 2016 Oct 27
Active, not recruiting
Phase 3
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults Start of enrollment: 2016 Oct 28
Active, not recruiting
Phase 3
Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed Start of enrollment: 2017 Jun 12
Completed
Phase 3
A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care Start of enrollment: 2017 Jul 31
Completed
Phase 3
Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011) Start of enrollment: 2017 Nov 27
Completed
Phase 2
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018) Start of enrollment: 2018 Jul 06
Completed
Phase 3
Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults Start of enrollment: 2018 May 30
Completed
Phase 3
Join now to see all

Other Languages

Spanish